Jia-Wei Wan1, Ming-Zhu Gao1, Rong-Jun Hu1, Hong-Yu Huang1, Yu-Yun Wei1, Zhi-Jun Han1, Zi-He Yan1. 1. 1 Department of Laboratory Medicine, Wuxi Second People's Hospital of Nanjing Medical University, Wuxi 214002, China ; 2 School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang 212013, China ; 3 Shanghai Genosaber Biotech Co. Ltd, Shanghai 200001, China.
Abstract
BACKGROUND: To evaluate the clinical value of circulating tumor cells (CTC) count in peripheral venous blood of patients with non-small cell lung carcinoma (NSCLC). METHODS: A total of 50 NSCLC patients who were diagnosed in Wuxi No. 2 People's Hospital from January 2013 to December 2013 were selected as the NSCLC group, 35 patients with lung benign tumor as the benign group, and 28 healthy subjects as the normal control group. Venous blood samples (3 mL) were collected in all subjects for counting the CTC, and a result of ≥8.7 was judged to be positive. The relationships between the positive rate of CTC and the age, sex, pathological type, and clinical stage of NSCLC were analyzed. RESULTS: CTC count was significantly higher in NSCLC group than in benign group and normal control group. In NSCLC patients, CTC count was not significantly correlated with sex, age, or the pathological type (P>0.05) but was closely related to clinical stage (P<0.01). Among NSCLC patients, CTC count significantly increased along with tumor progression. CONCLUSIONS: CTC count shows certain correlation with the clinical features of NSCLC and thus can, to certain extent, reflect the status of the disease.
BACKGROUND: To evaluate the clinical value of circulating tumor cells (CTC) count in peripheral venous blood of patients with non-small cell lung carcinoma (NSCLC). METHODS: A total of 50 NSCLCpatients who were diagnosed in Wuxi No. 2 People's Hospital from January 2013 to December 2013 were selected as the NSCLC group, 35 patients with lung benign tumor as the benign group, and 28 healthy subjects as the normal control group. Venous blood samples (3 mL) were collected in all subjects for counting the CTC, and a result of ≥8.7 was judged to be positive. The relationships between the positive rate of CTC and the age, sex, pathological type, and clinical stage of NSCLC were analyzed. RESULTS: CTC count was significantly higher in NSCLC group than in benign group and normal control group. In NSCLCpatients, CTC count was not significantly correlated with sex, age, or the pathological type (P>0.05) but was closely related to clinical stage (P<0.01). Among NSCLCpatients, CTC count significantly increased along with tumor progression. CONCLUSIONS: CTC count shows certain correlation with the clinical features of NSCLC and thus can, to certain extent, reflect the status of the disease.
Authors: Nikki Parker; Mary Jo Turk; Elaine Westrick; Jeffrey D Lewis; Philip S Low; Christopher P Leamon Journal: Anal Biochem Date: 2005-03-15 Impact factor: 3.365
Authors: Daniel C Christoph; Bernadette Reyna Asuncion; Biftu Hassan; Cindy Tran; Julia D Maltzman; Daniel J O'Shannessy; Murry W Wynes; Thomas C Gauler; Jeremias Wohlschlaeger; Mathias Hoiczyk; Martin Schuler; Wilfried E Eberhardt; Fred R Hirsch Journal: J Thorac Oncol Date: 2013-01 Impact factor: 15.609
Authors: Daniel J O'Shannessy; Gordon Yu; Robert Smale; Yao-Shi Fu; Sunil Singhal; Robert P Thiel; Elizabeth B Somers; Anil Vachani Journal: Oncotarget Date: 2012-04